Back to search results

Vitamin K and Knee Osteoarthritis Study

This study is looking at how different types and doses of vitamin K might help people with knee osteoarthritis (OA). Researchers want to see if taking Vitamin K1 (500 µg or 1000 µg daily) or Vitamin K2 (MK-7) (300 µg daily) for four weeks can change certain levels in your body related to vitamin K. You would be compared to people taking a placebo (an inactive pill). We don't know yet if these vitamin K doses are enough to help with OA. This study is open to men aged 50 and older, and women aged 60 and older, who have been diagnosed with knee OA and speak English. We are planning to enroll 55 participants, but the current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is a pilot randomized clinical trial, and will involve approximately 55 participants.
What's involved
You would take one pill daily for 4 weeks. Your uncarboxylated matrix Gla protein (ucMGP) and phylloquinone levels would be measured at the beginning of the study and again after 4 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 4 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06385275

The Role of Vitamin K on Knee Osteoarthritis Outcomes

Active, Not Recruiting
PHASE1Ages 50+InterventionalTreatment
Boston University
~49 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Vitamin K1 500 µgK1 1000 µgVitamin K2 (MK-7) 300 µgPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in uncarboxylated matrix Gla protein (ucMGP) levels
Measured over Baseline, 4 weeks
+3 more outcomes measured

Conditions

Osteo Arthritis Knee

Explore related trials

Osteoarthritis of knee

NCT06385275

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Boston Medical Center, Rheumatology Clinic

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jean Liew, MD MS · PRINCIPAL_INVESTIGATOR · Boston University Chobanian & Avedisian School of Medicine, Department of Rheumatology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men ≥50 years old
Women ≥60 years old
Clinical diagnosis of knee OA by the treating rheumatologist
English fluency

Exclusion

Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)

What this trial measures

  • Change in uncarboxylated matrix Gla protein (ucMGP) levelsBaseline, 4 weeks

    Plasma ucMGP levels will be measured from blood samples using an enzyme-linked immunoassay (ELISA).

  • Change in phylloquinone levelsBaseline, 4 weeks

    Plasma phylloquinone will be measured using high-pressure liquid chromatography (HPLC).

  • Sufficient phylloquinone levelsBaseline, 4 weeks

    Defined as the the proportion of participants achieving phylloquinone level of \>1.0 nmol/L, which is the level achieved when adequate intakes are met.

  • Change in menaquinone-7 (MK-7) levelsBaseline, 4 weeks

    Menaquinone-7 (MK-7) will be measured from blood samples using HPCL.